| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 1.2K | 3.2% |
| Total Income | 1.2K | 3.7% |
| Expenditure | 1.1K | 2.7% |
| PBT | 103.25 | 8.5% |
| Net Profit | 85.62 | 4.9% |
| OPM | 16.00% | 15.42pp |
| NPM | 7.12% | 0.56pp |
| EPS | 8.92 | 6.7% |
Strides Pharma Science Ltd Delivers Strong FY25 Results, Exceeding Outlook Across All Metrics
22 May 2025 · 22 May 2025, 01:40 pm
Summary
Strides Pharma Science Ltd announced its consolidated financial results for the quarter and full year ended March 31, 2025. The company's revenue grew by 17.2% YoY, outperforming the guidance of 12-15%. EBITDA grew by 36.8% YoY to 8,028m with EBITDA margin at 17.6%. US revenue grew by 21.8% YoY to $291m. The company reduced net debt by $5,128m and improved its Net Debt-to-EBITDA ratio to 1.9x. The Board has recommended a dividend of 4 per share for FY25.
Key Highlights
- 1
Revenue at 45,653m, grew 17.2% YoY
- 2
Gross margin at %25,854m, grew 20.5% YoY
- 3
EBITDA grew 36.8% YoY to 8,028m with EBITDA margin at 17.6%, grew 252bps YoY
- 4
US revenue at $291m, grew 21.8% YoY
- 5
Operational PAT at %3,447m, Grew 12x YoY
- 6
Operational EPS at 37.5, Grew 12x YoY
- 7
Q4FY25 Performance Highlights: Revenue at %11,904m, grew 17.0% YoY
- 8
EBITDA grew 22.0% YoY to =2,179m with EBITDA margin at 18.3%, grew 75bps YoY
- 9
US revenue at $77m, grew 23.2% YoY
- 10
Operational PAT at %1,130m, Grew 5x YoY
- 11
Operational EPS at 12.3, Grew 5x YoY
- 12
Reduced Net debt by %5,128m, and Net Debt-to-EBITDA ratio improved to 1.9x
Management Comments
Arun Kumar
Founder & Non-Executive Chairperson
We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12-15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering 8,028m in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger.
Badree Komandur
MD & Group CEO
As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders.
Informational and educational content only. Not investment advice.